{
  "docId": "019de071-7055-71be-8e36-ff3241c1e380",
  "docSlug": "06f5a1d0d7573c1d13069d999ff5f2e2",
  "documentTitle": "RenovoRx | IPO Presentation Deck | 29 slides",
  "authorId": "renovorx",
  "authorName": "RenovoRx",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 22,
  "pageCount": 29,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines a clinical trial design comparing standard IV Gemcitabine + Abraxane against RenovoGem intra-arterial treatment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-7055-71be-8e36-ff3241c1e380/22",
  "deckHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380",
  "deckJsonHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380.json",
  "deckAnchorHref": "/decks/019de071-7055-71be-8e36-ff3241c1e380#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Induction phase leading to 1:1 randomization into control and test arms, followed by continuation therapy and survival outcome measurement.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a375ae47-256e-482d-aecb-7e5b3f13b801",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.2,
        "y": 0.9
      },
      "kind": "paragraph",
      "text": "Pre-planned interim analysis at 65 deaths (estimated H2 2022)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "848c628f-cfdc-4d4e-bd99-84386bb9cea4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.7,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "* Choice of IV Gem/Abraxane or oral Capecitabine",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad33df17-b11e-4485-9cae-b1558bf3520e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Designed for Success: One Phase 3 Trial to FDA Approval",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c10de0ec-1574-4f81-adae-b247ee746986",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "Pivotal TIGeR-PaC Phase 3 Study Schema (Currently Enrolling)",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04cb6cbc-b9f2-4899-86c7-94713c116630",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "9975f8f2-8d98-48c3-ab72-756de8e6a058",
      "evidence": "Induction phase leading to 1:1 randomization into control and test arms, followed by continuation therapy and survival outcome measurement",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "707f5e92-04e1-4171-8233-bb4148312879",
      "evidence": "The slide uses a flow diagram to represent the clinical trial stages.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "eeb5d12f-412a-4325-8fbd-2a39f305b6d7",
      "evidence": "Slides 4 and 28 present the executive summary and investment highlights",
      "position": 1,
      "objective": "Present the investment highlights and ask",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}